Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group

Journal of Clinical Oncology

Volumn 22, Issue 24, 2004, Pages 4926-4933

  Lenz, Georg ^a   Dreyling, Martin ^a   Schiegnitz, Eva ^a   Haferlach, Torsten ^a   Hasford, Joerg ^a   Unterhalt, Michael ^a   Hiddemann, Wolfgang ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; STANDARDIZATION; TREATMENT OUTCOME; ACUTE DISEASE; ADULT; ARTICLE; AUTOTRANSPLANTATION; FEMALE; INCIDENCE; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MYELOID LEUKEMIA; NONHODGKIN LYMPHOMA; RADIOTHERAPY; RISK FACTOR; SECOND CANCER; STEM CELL TRANSPLANTATION;

ACUTE DISEASE; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LEUKEMIA, MYELOID; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY; PREDNISONE; PROSPECTIVE STUDIES; RADIOTHERAPY; RISK FACTORS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 16244362857     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.06.016     Document Type: Review

References (25)

1. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
2. Horning SJ, Negrin RS, Hoppe RT, et al: High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: Results of a phase II clinical trial. Blood 97:404-409, 2001
3. Colombat P, Cornillet P, Deconinck E, et al: Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: A GOELAMS phase II study. Bone Marrow Transplant 26:971-977, 2000
4. Lenz G, Dreyling M, Schiegnitz E, et al: Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Blood 104:2667-2674, 2004
5. Sebban C, Belanger C, Brousse N, et al: Comparison of CHVP + interferon with CHOP followed by autologous stem cell transplantation with a TBI conditioning regimen in untreated patients with high tumor burden follicular lymphoma: Results of the randomized GELF94 Trial (GELA Study Group). Blood 102:354, 2003 (abstr 354)
6. Hiddemann W, Dreyling MH, Pfreundschuh M, et al: Myeloablative radiochemotherapy followed by autologous blood stem cell transplantation leads to a significant prolongation of the event-free survival in patients with mantle cell lymphoma (MCL): Results of a prospective randomized European Intergroup study. Blood 98:861, 2001 (abstr 3572)
7. Micallef IN, Lillington DM, Apostolidis J, et al: Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 18:947-955, 2000
8. Howe R, Micallef IN, Inwards DJ, et al: Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma. Bone Marrow Transplant 32:317-324, 2003
9. Sobecks RM, Le Beau MM, Anastasi J, et al: Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant 23:1161-1165, 1999
10. Milligan DW, Ruiz De Elvira MC, Kolb HJ, et al: Secondary leukaemia and myelodysplasia after autografting for lymphoma: Results from the EBMT: EBMT Lymphoma and Late Effects Working Parties-European Group for Blood and Marrow Transplantation. Br J Haematol 106:1020-1026, 1999
11. Krishnan A, Bhatia S, Slovak ML, et al: Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors. Blood 95:1588-1593, 2000
12. Armitage JO, Carbone PP, Connors JM, et al: Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 21:897-906, 2003
13. Tucker MA, Coleman CN, Cox RS, et al: Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 318:76-81, 1988
14. Travis LB, Curtis RE, Boice JD Jr, et al: Second cancers following non-Hodgkin's lymphoma. Cancer 67:2002-2009, 1991
15. Jaffe ES, Harris NL, Stein H, et al: World Health Organisation Classification of Tumours: Tumours of the Haemopoitic and Lymphoid Tissues. Lyon, France, IARC Press, 2001
16. Marubini E, Valsecchi M: Analysing Survival Data From Clinical Trials and Observational Studies. New York, NY, Wiley & Sons, 1995
17. Deconinck E, Foussard C, Bertrand P-P, et al: Value of autologous stem cell transplantation in first-line therapy of follicular lymphoma with high tumor burden: Final results of the randomized GOELAMS 064 Trial. Blood 102:246, 2003 (abstr 865)
18. Darrington DL, Vose JM, Anderson JR, et al: Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 12:2527-2534, 1994
19. Metayer C, Curtis RE, Vose J, et al: Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: A multicenter case-control study. Blood 101:2015-2023, 2003
20. Andersson M, Philip P, Pedersen-Bjergaard J: High risk of therapy-related leukemia and preleukemia after therapy with prednimustine, methotrexate, 5-fluorouracil, mitoxantrone, and tamoxifen for advanced breast cancer. Cancer 65:2460-2464, 1990
21. Travis LB, Curtis RE, Stovall M, et al: Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst 86:1450-1457, 1994
22. Linassier C, Barin C, Calais G, et al: Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. Ann Oncol 11:1289-1294, 2000
23. Saso R, Kulkarni S, Mitchell P. et al: Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma. Br J Cancer 83:91-94, 2000
24. de Witte T, Suciu S, Peetermans M, et al: Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration: A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia 9:1805-1811, 1995
25. Kantarjian HM, Keating MJ, Walters RS, et al: Therapy-related leukemia and myelodysplastic syndrome: Clinical, cytogenetic, and prognostic features. J Clin Oncol 4:1748-1757, 1986